H.S.H. Prince Albert II of Monaco, Principality of Monaco, Monaco
Sir Christopher Mallaby, London, United Kingdom
Comte Diego du Monceau de Bergendal, Brussels, Belgium
Sir David Tang KBE, Hong Kong
Professor John Smyth, Edinburgh, United Kingdom
Mrs. Victoria Agnew, London, United Kingdom
Who we are?
Founded in 1976, the EORTC Foundation was established by Royal Decree under the laws of the Kingdom of Belgium as an international association under Belgian Law with the specific aim of raising funds for the activities of the EORTC, to support the structure of the organization and independent academic research projects.
In 2006, the EORTC Foundation changed its name to The EORTC Charitable Trust to adapt to new Belgian legislation but the aims of The EORTC Charitable Trust remained unchanged. In April 2015, The EORTC Charitable Trust changed its name to EORTC Cancer Research Fund. This is to ensure that our name reflects very clearly the areas of our activity in raising support worldwide for EORTC’s cancer research projects.
Our cancer research funding mission
The Mission of EORTC Cancer Research Fund is to raise financial support for the cancer research activities of the EORTC. EORTC Cancer Research Fund receives substantial funds from various national cancer charities; it also actively seeks other funds whenever possible to support EORTC’s independent academic research projects. Should you or your organization wish to sponsor an EORTC cancer research project or program please contact us as we will be pleased to discuss this with you. Please contact Victoria Agnew, Director of EORTC Cancer Research Fund: Tel: +44 207 917 9917; Fax: +44 207 439 0262/ 207 917 6821; Mobile: +44 7776 186 943; Email: firstname.lastname@example.org
How we operate?
EORTC Cancer Research Fund is governed by the Members of its Board/General Assembly. This is made up of private individuals from many countries who support our work, as well as senior members of the national cancer charities and distinguished oncologists from all over Europe.
Two independent committees have been created recently to add further improvement to this governance: an “Independent Finance Committee” whose task will be to give to the Boards of EORTC and EORTC Cancer Research Fund its neutral opinion and advice on all aspects regarding financial management, audit and investment management; and, a “Communication and Fundraising Committee” to help the organization in these fields.
Members of the General Assembly
All major European national cancer charities which support the work of the EORTC are represented in the General Assembly, as well as the Hong Kong Cancer Fund.
Chairman: Comte Diego du Monceau de Bergendal, Brussels (BE)
Vice-Chairmen: Sir David Tang KBE, Hong Kong and Professor John Smyth, Edinburgh (GB)
Director: Mrs. Victoria Agnew, London (GB)
Mr Guy Beniada, Brussels (BE)
Professor Jean-Yves Blay, Lyon (FR)
Mr. Christian Boel, Hellerup (DK)
Dr. Gérard Depadt, Lille (FR)
Professor Alexander M.M. Eggermont, Villejuif (FR)
H.E. Ambassador Evelyne Genta, Monaco (MC)
Dr. Jean de Gunzburg, London (GB)
Mr. Luc van Haute, Brussels (BE)
Ms. Karen Heasley, London (GB)
Mrs. Elizabeth Hjorth, Copenhagen (DK)
Professor Jean-Claude Horiot, Genolier (CH)
Professor Klas Kärre, Stockholm (SE)
Dr Denis Lacombe, Brussels (BE)
Comte Aymar de Lastours, Paris (FR)
Mr. Erwin Lauwers, Brussels (BE)
Mr. Marc Leland, London (GB)
Mr. Oscar M. Lewisohn, London (GB)
Mrs. Sally Lo MBE, Hong Kong (HK)
Mrs. Renilde Loeckx, Washington DC (USA)
H.R.H. Prince Guillaume of Luxembourg, Contern (LU)
Dr. Rolf Marti, Bern (CH)
Professor J. Gordon McVie, Milan (IT)
Professor Françoise Meunier, Brussels (BE)
Mr. Ole Alexander Opdalshei, Oslo (NO)
Professor Martine Piccart, Brussels (BE)
H.E. Ambassador Marie-Thérèse Pictet-Althann, Geneva (CH)
Mrs. Suzan Sabanci-Dinçer, Istanbul (TR)
Mrs. Bruno Schroder, London (GB)
Mr. Jean-Léopold Schuybroek
Mrs. Cigdem Simavi, Istanbul (TR)
Lady Solti, London (GB)
Professor Roger Stupp, Zurich (CH)
Mr. Robert Waley-Cohen, London (GB)
Milestones in our history
1976 Creation of the EORTC Foundation. HRH Prince Philip, the Duke of Edinburgh becomes the first Honorary President.
1992 H.M. Queen Sofia of Spain becomes Honorary President.
1997 H.M. Queen Silvia of Sweden becomes Honorary President.
2003 H.R.H Princess Astrid of Belgium becomes Honorary President.
2014 – (Current)
H.R.H Princess Astrid of Belgium, Honorary President of the EORTC Cancer Research Fund stepped down after serving the cause very loyally for 11 years.
H.S.H Prince Albert II of Monaco succeeds her as Honorary President of the EORTC Cancer Research Fund in February 2014.
Sir Ronald Grierson, founding Chairman of the EORTC Foundation from 1976 to 1990, retires in his capacity as Honorary Vice President in 2014. His era was marked by tireless energy and commitment to the cause as well by his efforts to raise awareness on the importance of clinical trials to allow for better treatments. Sadly, Sir Ronald Grierson passed away in October 2014.
Sir Christopher Mallaby was Chairman from 2000 before retiring in March 2014 to become Honorary Vice President.
Comte Diego du Monceau de Bergendal becomes Chairman in March 2014.
Professor John Smyth becomes a Vice Chairman of the EORTC Cancer Research Fund in March 2014.
Some recent cancer research funding achievements
Thanks to its wide network of contacts and friends, the EORTC Cancer Research Fund raised considerable support over the last 30 years. Between the years 2006 and 2012, nearly € 18 million was raised to support the work of the EORTC in its relentless mission to prolong and ultimately save lives of cancer sufferers. This financial support has been achieved mainly through a combination of sources, including the national cancer charities, donations from private individuals, foundations and companies; funds raised through international gala events and specific corporate social responsibility programs from companies. Below are some examples of our recent funding successes.
2011 The EORTC Charitable Trust entered into an important partnership with Alliance Boots (now Walgreens Boots Alliance), the international pharmacy and beauty products group, to create the EORTC’s SPECTAcolor Biobank for Colorectal Cancer. Walgreens Boots Alliance has committed to providing €5,000,000 over five years for this project by fundraising through its companies in Europe. Since the inception of the project in 2012, nearly €3,500,000 has been raised by the staff and employees of the Alliance Boots companies all over Europe.
2012-2013 Leukemia in the elderly (ongoing): Project sponsored by The ‘HRH Prince Alwaleed Foundation’. The first phase is now completed and the research project was presented at the American Society of Hematology’s highly prestigious conference in New Orleans, (USA).
2013 EORTC Cancer Research Fund received an annual core support of €1.3 million from various European national cancer charities and the Hong Kong Cancer Fund and made a core grant of this amount to the EORTC.
2013 Launch of the Sallie Snowman Survivorship Initiative: Study of key clinical questions concerning long term cognitive effects in patients after a cancer treatment. This initiative also addresses cancer socio-economical and psychological issues.
2014 Transatlantic Rare Cancers Initiative for which the EORTC Cancer Research Fund has received a commitment for an annual contribution towards the study for several years and will continue to work to raise more funds.
Over 113 research fellowships have been awarded by the EORTC Cancer Research Fund to young oncologists from 30 different countries worldwide. Established in 1991 the EORTC Fellowship Program promotes European clinical cancer research by offering training in the methodology of high-quality cancer clinical trials. It fosters specific research projects on EORTC clinical trials, quality assurance and quality of life (QoL). The program allows the fellows to accomplish a research project and/or PhD thesis based on data available in the EORTC Database. These fellowships also provide an opportunity for applicants to become familiar with practical aspects of clinical research including clinical trial methodology, regulatory affairs, data management, statistics, medical monitoring and the reporting of results. The fellows come from all over the world to stay for a minimum of a year and up to three years at EORTC in Brussels. Medical doctors, biostatisticians, computer analysts and other scientists are entitled to apply for these fellowships which are specifically linked to the research programs of the EORTC groups or EORTC specific research projects.
Financial support for these fellowships is received from some of the national cancer charities, companies, foundations and private individuals.
“An EORTC Fellowship opens the door to a career in cancer clinical and translational research“
The EORTC Cancer Research Fund wishes to thank all its donors for their support and generosity over many years. Your recognition and understanding of the vital importance of the cancer research work carried out by the EORTC has made our achievements of the past 50 years possible for the benefit of all cancer patients.
“The EORTC – 50 years of progress and research against cancer”
Should you wish to contribute to improve the standard of cancer treatments, increase survival and patient quality of life, please donate !
“Your donation will help the EORTC forge the future of cancer therapy”
Comte Diego du Monceau de Bergendal, Chairman
Mrs. Victoria Agnew, Director
EORTC Cancer Research Fund
London W1J 9HF
Tel: +44 207 917 9917
Fax: +44 207 439 02 62
Account number: 068-2429274-33
Belfius Banque SA
Avenue de l’Eglise, 10 B
BE – 1150 Brussels, Belgium